Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Entrada Therapeutics, Inc. (TRDA) had Normalized Pre-Tax Income of $-42.73M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.90M |
|
$-42.76M |
|
-- |
|
$0.90M |
|
$45.86M |
|
$-44.96M |
|
$2.23M |
|
$-42.73M |
|
|
Normalized Pre-Tax Income |
$-42.73M |
$-42.76M |
|
$-42.76M |
|
$-42.76M |
|
$-42.76M |
|
$-44.96M |
|
$-44.57M |
|
42.22M |
|
42.22M |
|
$-1.01 |
|
$-1.01 |
|
| Balance Sheet Financials | |
$232.70M |
|
$5.72M |
|
$66.17M |
|
$298.88M |
|
$21.37M |
|
-- |
|
$44.09M |
|
$65.47M |
|
$233.41M |
|
$233.41M |
|
$233.41M |
|
38.94M |
|
| Cash Flow Statement Financials | |
$-74.16M |
|
$81.94M |
|
$0.45M |
|
$94.34M |
|
$102.57M |
|
$8.23M |
|
$9.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.89 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-5007.02% |
|
-5007.02% |
|
-- |
|
-4758.13% |
|
-4762.03% |
|
$-74.21M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
1.10 |
|
81.78 |
|
-18.32% |
|
-18.32% |
|
-14.31% |
|
-18.32% |
|
$5.99 |
|
$-1.76 |
|
$-1.76 |
|